Devyser Diagnostics
128.5
SEK
0 %
DVYSR
First North Stockholm
Medical Equipment & Services
Health Care
Less than 1K followers
0%
-0.39%
+8.44%
-3.38%
+20.09%
+49.07%
+55.19%
-
+44.38%
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Read moreMarket cap
2.13B SEK
Turnover
1.32M SEK
Revenue
216.9M
EBIT %
-26.88 %
P/E
-
Dividend yield-%
-
Financial calendar
29/4
2025
Interim report Q1'25
14/5
2025
General meeting '25
22/7
2025
Interim report Q2'25
ShowingAll content types
Devyser secures a major SEK 16.8M tender in Italy with 30% growth
Redeye: Devyser Q4 - Looking strong on corrected numbers
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Rättelse: För låg direktförsäljning rapporterad i bokslutskommuniké "Devyser Diagnostics AB publicerar bokslutskommuniké för januari till december 2024"
Correction: Too low direct sales reported in year-end report "Devyser Diagnostics AB publishes year-end report for January to December 2024"
